{"id":"W2515018033","doi":"10.1016/j.jid.2016.06.071","title":"054 Treatment with ixekizumab over 60 weeks provides sustained improvements in health-related quality of life: Results from UNCOVER-1, a randomized phase 3 trial","year":2016,"lang":"en","type":"article","venue":"Journal of Investigative Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"XLV Diagnostics (Canada); Dalhousie University","funders":"","keywords":"Ixekizumab; Medicine; Quality of life (healthcare); Internal medicine; Secukinumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001678863,0.001196739,0.002881285,0.0004072906,0.0005441103,0.001472462,0.0008245143,0.001831184,0.006531274],"category_scores_gemma":[0.001231521,0.0005503398,0.002868845,0.0003642953,0.001076668,0.00132918,0.0003642562,0.003376009,0.001212353],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006306995,"about_ca_system_score_gemma":0.0007082246,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007434669,"about_ca_topic_score_gemma":0.001179218,"domain_scores_codex":[0.9994282,0.0002167141,0.00004207105,0.0001151067,0.00006239433,0.0001354417],"domain_scores_gemma":[0.9993165,0.0002181026,0.0001816673,0.00005955422,0.00004196649,0.0001822872],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9261909,0.009409085,0.001265222,0.001024051,0.002169657,0.00005378497,0.00006820093,0.0004506482,0.005001301,0.0001612978,0.0015154,0.0526905],"study_design_scores_gemma":[0.899874,0.09249529,0.004251713,0.00007253315,0.001032814,0.00006055611,0.00005267422,0.0004209603,0.0007493956,0.0002284536,0.0007369475,0.00002462949],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9870017,0.006894256,0.0006093066,0.0008216248,0.0003854962,0.0009328328,0.0009127561,0.0001871212,0.002255027],"genre_scores_gemma":[0.990178,0.003078657,0.001041483,0.001131089,0.0003720008,0.0007998057,0.001018168,0.0000435303,0.002337151],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006531274,"threshold_uncertainty_score":0.02184927,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03533127684654822,"score_gpt":0.2981473661478036,"score_spread":0.2628160893012553,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}